U.S. health regulators approved Roche’s arthritis drug Actemra for emergency use to treat hospitalized Covid-19 patients, giving an extra boost to a medicine that was already allowed to be administered on compassionate grounds.
U.S. scientists are expanding a government-funded study that aims to directly answer the question of whether Moderna Inc.’s Covid-19 vaccine curbs the spread of SARS-CoV-2.
Younger adults are seeking out Covid-19 vaccines at a slower rate than older adults, and if that pace of vaccination continues through August, vaccine coverage among younger adults will not reach levels achieved with older adults, U.S. Centers for Disease Control and Prevention (CDC) reported on June 21.
The U.S. Food and Drug Administration approved Pfizer Inc.’s Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes in the vaccine in adults ages 18 years and older.
The U.S. Food and Drug Administration granted marketing clearance for Ryplazim as the first FDA-approved therapy for the treatment of patients with the plasminogen deficiency type 1 (hypoplasminogenia), a rare genetic disorder.
The U.S. Food and Drug Administration on June 4 approved Danish drugmaker Novo Nordisk’s once-weekly semaglutide drug as a treatment for obesity, a condition that affects nearly 70% of American adults.
The U.S. Food and Drug Administration approved Biohaven Pharmaceutical Holding Company Ltd.’s Nurtec ODT (rimegepant 75 mg) for the preventive treatment of migraine. Nurtec ODT is indicated for adult patients with episodic migraine, e.g. those who experience less than 15 headache days per month.
Some teenagers and young adults who received Covid-19 vaccines experienced heart inflammation, a U.S. Centers for Disease Control and Prevention advisory group said, recommending further study of the rare condition.
Medicago and GlaxoSmithKline reported positive interim Phase 2 clinical trial safety and immunogenicity data for Medicago’s plant-derived Covid-19 vaccine candidate, which has been tested in combination with GSK’s pandemic adjuvant.
Sanofi and GlaxoSmithKline reported positive data on their Covid-19 vaccine candidate in all adult age groups in a Phase II trial of 722 volunteers. The companies expect to launch a global pivotal Phase III trial in the coming week.